Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC) (CROSBI ID 616603)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Von Minckwitz, G ; Puglisi, F ; Cortes, J ; Vrdoljak, E ; Marschner, N ; Zielinski, C ; Villanueva CB ;
engleski
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2- negative locally recurrent/metastacic breast cancer (LR/MBC)
Efficacy and safety in Tania, a randomised phase III trial of continued or reintroduced bevacizumab (bev) after 1st-line bev for HER2-negative locally recurrent/metastacic breast cancer (LR/MBC)
breast cancer; metastatic
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2014.
objavljeno
Podaci o matičnoj publikaciji
Podaci o skupu
Annals of Oncology
poster
01.01.2014-01.01.2014
Ujedinjeno Kraljevstvo
